How long does it take to stop taking Imatinib (Gleevec) and analysis of the safety of stopping the drug

Imatinib (Imatinib) is an oral tyrosine kinase inhibitor (TKI), since pan>2001Approved for the treatment of **chronic myelogenous leukemia (CML)**, it has become the first-line standard treatment drug forCML, and is also suitable for some gastrointestinal stromal tumors (GIST) and other c-KIT or PDGFR related diseases. Imatinib blocks tumor cell proliferation and signal transduction by selectively inhibiting the activity of tyrosine kinases such as BCR-ABL fusion protein, c-KIT c-KIT and PDGFR, thereby effectively controlling disease development. In CML patients, imatinib significantly improved progression-free survival and overall survival, allowing many patients to maintain disease remission for a long time and even consider phasing out the drug when conditions permit.

As for when imatinib can be discontinued, the main clinical reference is the maintenance of deep molecular remission (DMR). Generally, for patients in the chronic phase of CML, if they have been taking imatinib continuously for at least 3 years and achieve and maintain MR4 or MR4 during treatment. 5level (BCR-ABL/ABLratio ≤0.01% or ≤0.0032%) for at least two years, drug discontinuation can be considered under strict monitoring. Studies have shown that among eligible patients, approximately 40% to 50% can maintain long-term treatment-free response after drug withdrawal (Treatment-Free Remission, TFR). However, some patients will still experience molecular relapse after discontinuation of treatment and need to restart imatinib treatment. The decision to discontinue medication must comprehensively consider factors such as patient age, disease duration, comorbid underlying diseases, and drug tolerance.

The safety of drug withdrawal mainly depends on strict molecular monitoring. Guidelines recommend the first 6Monthly, review every monthBCR-ABLmolecular level; 6 to 12Monthly review every 2 months; 12 months later, it can be extended to every 3 months. Once monitoring finds that BCR-ABL levels continue to increase or reach critical values, imatinib treatment needs to be resumed immediately. Clinical practice shows that most patients can quickly regain deep remission after resumption of treatment, and the process of discontinuation and resumption of treatment does not significantly affect long-term survival rate or increase treatment-related risks. Therefore, drug discontinuation is feasible and relatively safe under strict supervision, but must be guided by an experienced hematologist.

During the withdrawal process, attention should also be paid to individual differences and possible adverse reactions. Some patients may experience mild blood index fluctuations, mild fatigue or other short-term symptoms after stopping the drug, but generally no special treatment is required. At the same time, psychological factors cannot be ignored. Some patients may have anxiety due to fear of recurrence. Therefore, when making decisions about drug discontinuation, doctors need to fully communicate with patients and clarify the drug discontinuation plan, monitoring frequency, and resumption plan to reduce psychological pressure and improve compliance.

It is worth noting that stopping the drug does not mean a cure. Imatinib is more of a long-term disease control strategy. For some CML patients with a longer disease course or additional high-risk mutations, discontinuation of treatment may be associated with a higher risk of relapse, so long-term treatment is still required. For young patients with stable conditions and able to undergo strict follow-up, drug discontinuation can improve the quality of life, reduce adverse drug reactions and economic burden, thereby improving the overall life experience.

In general, discontinuation of imatinib is an individualized, step-by-step strategy. Patients need to be evaluated by a professional doctor and develop a discontinuation plan on the premise of achieving deep molecular remission, maintaining stability, and being able to cooperate with regular monitoring. During the period of drug withdrawal, regular hematological and molecular review is the core measure to ensure safety and efficacy. Once there are signs of recurrence, medication should be resumed immediately to ensure that the condition is controllable. Through scientific management and strict follow-up, many CML patients can maintain no response to treatment for a long time after drug withdrawal, while reducing drug side effects and life burden, making it possible to achieve high-quality survival.

Reference materials:https://www.drugs.com/